Illumina, Inc.
(NASDAQ : ILMN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.08%171.441.3%$495.59m
BIIBBiogen Inc.
-1.21%232.191.3%$474.53m
CELGCelgene Corporation
-0.28%96.091.3%$455.94m
GILDGilead Sciences, Inc.
0.96%67.140.9%$438.91m
ILMNIllumina, Inc.
-0.21%312.173.5%$317.03m
REGNRegeneron Pharmaceuticals, Inc.
-1.77%314.422.6%$293.32m
AAgilent Technologies, Inc.
-2.60%66.201.6%$202.25m
VRTXVertex Pharmaceuticals Incorporated
-0.53%171.461.9%$180.22m
EXASExact Sciences Corporation
-2.20%92.8225.3%$160.06m
ALXNAlexion Pharmaceuticals, Inc.
-1.30%125.892.0%$147.69m
BMRNBioMarin Pharmaceutical Inc.
-0.63%87.144.3%$117.80m
SRPTSarepta Therapeutics, Inc.
-1.68%119.5814.7%$110.26m
INCYIncyte Corporation
0.42%79.352.5%$106.16m
IONSIonis Pharmaceuticals, Inc.
-1.66%67.438.2%$97.11m
ALNYAlnylam Pharmaceuticals, Inc
-1.76%66.629.2%$93.27m

Company Profile

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.